Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Endocrine therapy is standard for ER+ breast cancer but limited by acquired resistance.
• Acquired resistance correlates with increased cellular invasion, migration, and CD44 family protein overexpression.
• CD44's association with tumor progression suggests a role in endocrine-resistant breast cancer aggressiveness.

Purpose of the Study:

• Investigate the role of CD44v3 and CD44v6 isoforms in endocrine-resistant breast cancer.
• Determine if CD44v6 overexpression promotes aggressive behavior and endocrine resistance.
• Explore the potential of targeting CD44v6 for overcoming endocrine resistance.

Main Methods:

• Overexpression of CD44v6 and CD44v3 in endocrine-sensitive MCF-7 cells.
• Assessment of EGFR signaling, invasive capacity, and response to endocrine treatment.
• Suppression of CD44v6 in endocrine-resistant cell models.

Main Results:

• CD44v6 overexpression, not CD44v3, enhanced EGFR signaling and invasive capacity in endocrine-sensitive cells.
• Overexpression of CD44v6 attenuated the response to endocrine treatment.
• CD44v6 suppression reduced invasiveness in endocrine-resistant models.
• Upregulation of CD44v6 may promote aggressive phenotype and endocrine resistance via EGFR pathway transactivation.

Conclusions:

• CD44v6 upregulation contributes to the aggressive phenotype and endocrine resistance in breast cancer.
• Targeting CD44v6, potentially with EGFR inhibitors, may be a strategy to delay or prevent acquired resistance.